Trial · NCT04982289
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
NCT04982289, Phase 2, Withdrawn, Alexion Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis. Trials, record NCT04982289. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04982289
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
- NCT number
- NCT04982289
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- ALXN1830, Placebo
- First posted
- 2021-07-29
- Last updated
- 2022-02-11
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events (AEs) And Serious Adverse Events (SAEs) Up To Week 24 | Up to Week 24 | |
| Primary | AEs And SAEs Up To Week 82 | Up to Week 82 (OLE) | |
| Primary | Change From Baseline In Serum Total Immunoglobulin G (IgG) | Up to Week 24 | |
| Secondary | Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score | Up to Week 24 | |
| Secondary | Change From Baseline In Quantitative Myasthenia Gravis (QMG) Score | Up to Week 24 | |
| Secondary | Number Of Participants With At Least A 2-point Improvement In The MG-ADL Score Over 4 Consecutive Weeks | Up to Week 24 | |
| Secondary | Number Of Participants With At Least A 3-point Improvement In The QMG Score Over 4 Consecutive Weeks | Up to Week 8 | |
| Secondary | Change From Baseline In Neurological Disorders Fatigue Questionnaire (Neuro-Qol) Fatigue Score | Up to Week 24 | |
| Secondary | Serum Trough Concentrations Of ALXN1830 | Up to Week 24 | |
| Secondary | Change From Baseline In IgG Subtypes | Up to Week 24 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04982289
GET https://conductscience.org/api/trials/v1/NCT04982289/registered